Conversely, IGF2BP2 stabilizes NFE2L2 mRNA, while IGF2BP3 overexpression helps maintain anti-ferroptotic transcripts (GPX4, SLC3A2, ACSL3, and FTH1) and confers sorafenib resistance in HCC [203,204]. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.